Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks
Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks Late-breaking results from I CAN Phase III trial will be
AstraZeneca's kidney medicine Ultomiris got fast approval from the FDA. It helped sick patients lose protein in their urine much better than a fake pill.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.